The estimated Net Worth of Erle T Mast is at least $5.99 Milhão dollars as of 1 February 2022. Mr. Mast owns over 1,250 units of Zogenix Inc stock worth over $114,110 and over the last 14 years he sold ZGNX stock worth over $5,476,643. In addition, he makes $396,018 as Independent Director at Zogenix Inc.
Erle has made over 18 trades of the Zogenix Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 1,250 units of ZGNX stock worth $15,000 on 1 February 2022.
The largest trade he's ever made was selling 50,000 units of Zogenix Inc stock on 10 December 2013 worth over $2,639,000. On average, Erle trades about 3,446 units every 107 days since 2010. As of 1 February 2022 he still owns at least 4,277 units of Zogenix Inc stock.
You can see the complete history of Mr. Mast stock trades at the bottom of the page.
Erle T. Mast serves as Independent Director of the Company. He has served as a member of our board of directors since May 2008. Mr. Mast was a co-founder of and served as Executive Vice President, Chief Financial Officer with Clovis Oncology, Inc., a biotechnology company, from May 2009 through March 2016. From July 2002 to May 2008, Mr. Mast served as Executive Vice President and Chief Financial Officer of Pharmion Corporation, until its acquisition by Celgene Corporation. From 2000 to 2002, after Elan Pharma International Ltd. acquired Dura Pharmaceuticals, Inc., Mr. Mast served as Chief Financial Officer for the Global Biopharmaceuticals business unit of Elan. From 1997 to 2000, Mr. Mast served as Vice President of Finance for Dura Pharmaceuticals. From 1984 to 1997, Mr. Mast held positions of increasing responsibility at Deloitte & Touche, LLP, serving most recently as partner, where he provided accounting, auditing and business consulting services to companies in various industries, including the healthcare, pharmaceutical, biotech and manufacturing industries. Mr. Mast served as a director for Sienna Biopharmaceuticals, Inc. from 2017 to 2018, for Somaxon Pharmaceuticals, Inc. from 2008 to 2013 and for Receptos Inc. from 2013 to 2015, each publicly traded biotechnology companies. As previously disclosed in September 2018, the SEC entered into a settlement with Clovis and certain of its executive officers, including Mr. Mast, relating to an SEC investigation into whether Clovis had violated federal securities laws in connection with Clovis’ disclosure in November 2015 that the FDA had requested additional clinical data on the efficacy and safety of a product under development by Clovis.
As the Independent Director of Zogenix Inc, the total compensation of Erle Mast at Zogenix Inc is $396,018. There are 12 executives at Zogenix Inc getting paid more, with Stephen Farr having the highest compensation of $10,346,800.
Erle Mast is 57, he's been the Independent Director of Zogenix Inc since 2008. There are 9 older and 11 younger executives at Zogenix Inc. The oldest executive at Zogenix Inc is Cam Garner, 71, who is the Independent Chairman of the Board.
Erle's mailing address filed with the SEC is C/O ZOGENIX, INC., 5959 HORTON STREET, SUITE 500, EMERYVILLE, CA, 94608.
Over the last 14 years, insiders at Zogenix Inc have traded over $5,100,850 worth of Zogenix Inc stock and bought 57,764,538 units worth $193,451,745 . The most active insiders traders include Advisors Llcperceptive Life..., Nicole Vitullo, eJesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of $13,059,406. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth $15,000.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Zogenix Inc executives and other stock owners filed with the SEC include: